ArticleOncotarget2018
Prediction of non-muscle-invasive bladder cancer recurrence by measurement of checkpoint HLAG's receptor ILT2 on peripheral CD8
Article in Oncotarget, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 21 citations in OpenAlex.
- Immune Phenotype in Urothelial Carcinoma: From Tumor Biology to Therapeutic Stratification.Cancers · 2026Review
- Inhibitory leukocyte immunoglobulin-like receptors, subfamily B (LILRBs) in human diseases: structure, roles, mechanisms, and clinical applications.Theranostics · 2025Review
- Article
- Induction of pulmonary HLA-G expression by SARS-CoV-2 infection.Cellular and molecular life sciences : CMLS · 2022Article
- Identification of an immune gene-associated prognostic signature in patients with bladder cancer.Cancer gene therapy · 2022Article
- Immune profiles and DNA methylation alterations related with non-muscle-invasive bladder cancer outcomes.Clinical epigenetics · 2022Article
- The Human Leukocyte Antigen G as an Immune Escape Mechanism and Novel Therapeutic Target in Urological Tumors.Frontiers in immunology · 2022Review
- First immunotherapeutic CAR-T cells against the immune checkpoint protein HLA-G.Journal for immunotherapy of cancer · 2021Article
- Leukocyte immunoglobulin-like receptor subfamily B: therapeutic targets in cancer.Antibody therapeutics · 2021Review
- Antagonistic anti-LILRB1 monoclonal antibody regulates antitumor functions of natural killer cells.Journal for immunotherapy of cancer · 2020Article
- Comprehensive landscape of immune-checkpoints uncovered in clear cell renal cell carcinoma reveals new and emerging therapeutic targets.Cancer immunology, immunotherapy : CII · 2020Article
- HLA-G and humanized mouse models as a novel therapeutic approach in transplantation.Human immunology · 2020Review
- HLA-G dimer targets Granzyme B pathway to prolong human renal allograft survival.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2019Article
- Prediction tools in non-muscle invasive bladder cancer.Translational andrology and urology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveRecurrence of non-muscle invasive bladder cancer (NMIBC) after initial management occurs in 60-70% of patients. Predictive criteria for recurrence remain only clinical and pathological. The aim of this study was to investigate the prognostic significance of the proportion of checkpoint HLA-G's receptor ILT2-expressing peripheral CD8
resultsThe proportion of CD4 MATERIALS AND
methodsAll patients treated for NMIBC between 2012 and 2014 were included prospectively. Blood samples, tumor and clinico-pathological characteristics were collected. HLA-G expression was measured using IHC, and CD8
conclusionsWe demonstrated a strong association between the proportion of circulating CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.